Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its second quarter net loss rose year over year as it continues to advance its lung cancer liquid biopsy test, DetermaVu.

For the three months ended June 30, the Alameda, California-based diagnostic developer incurred a net loss of 5.4 million, or $.10 per share, compared to $4.5 million, or $.12 per share, in the year-ago period. Analysts on average had expected a loss per share of $.09.

OncoCyte did not report any revenues for the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.